FDA Adverse Event Injury Summary report: N

UNKN BIRMINGHAM HIP RESURFACING (BHR) HEAD

MDR report key: 14744066 · Received June 20, 2022

Report

Report Number
3005975929-2022-00405
Event Type
Injury
Date Received
June 20, 2022
Date of Event
July 21, 2021
Report Date
July 11, 2022
Manufacturer
SMITH & NEPHEW ORTHOPAEDICS LTD
Product Code
NXT
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
VA, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

INTERNAL COMPLAINT REFERENCE: (B)(4). SU, E. P., HO, H., BHAL, V., HOUSMAN, L. R., MASONIS, J. L., NOBLE JR, J. W., & ENGH JR, C. A. (2021). RESULTS OF THE FIRST US FDA-APPROVED HIP RESURFACING DEVICE AT 10-YEAR FOLLOW-UP. JBJS, 103(14), 1303-1311. DOI: 10.2106/JBJS.20.01886.

Additional Manufacturer Narrative · 0

H3, H6: IT WAS REPORTED THAT, ON LITERATURE REVIEW ""RESULTS OF THE FIRST U.S FDA - APPROVED HIP RESUFACING DEVICE AT 10 - YEAR FOLLOW - UP. "", OSTEOLYSIS WAS IDENTIFIED IN FOUR OUT OF TWO HUNDRED EIGHTEEN FEMORAL COMPONENTS IMPLANTED ON PATIENTS WHO UNDERWENT PRIMARY SURGERY WITH A BHR RESURFACING CONSTRUCT. ALTHOUGH IT IS UNKNOWN HOW THIS EVENT WAS ADDRESSED ON EACH PATIENT, A REVISION SURGERY WAS NOT REQUIRED, THEREFORE THE DEVICES, USED IN TREATMENT, WERE NOT AVAILABLE FOR ANALYSIS. AS NO DEVICE PART AND BATCH NUMBERS WERE PROVIDED FOR INVESTIGATION, A COMPLAINT HISTORY REVIEW, MANUFACTURING RECORD REVIEW, DEVICE LABELLING / IFU REVIEW COULD NOT BE PERFORMED. IF MORE INFORMATION IS RECEIVED, THIS INVESTIGATION WILL BE REOPENED. A REVIEW OF HISTORIC ESCALATION ACTIONS RELATED TO THE PRODUCTS AND SIMILAR COMPLAINT EVENTS WAS PERFORMED. FOLLOWING THE REVIEW, PRIOR APPLICABLE ESCALATION ACTIONS WERE IDENTIFIED AND CONFIRMED TO REDUCE ASSOCIATED RISKS AS FAR AS POSSIBLE. NO FURTHER ESCALATION ACTIONS ARE REQUIRED. A RISK MANAGEMENT REVIEW WAS PERFORMED FOR THE ACETABULAR CUP AND FEMORAL HEAD. THE ALLEGED FAILURE MODES AND ASSOCIATED RISKS HAVE BEEN ANTICIPATED WITHIN THE RISK FILE AND THE ANTICIPATED RISK LEVEL IS STILL ADEQUATE. NO FURTHER ACTIONS ARE REQUIRED AT THIS TIME. WITHOUT CLINICALLY RELEVANT PATIENT-SPECIFIC SUPPORTING DOCUMENTATION, A THOROUGH MEDICAL INVESTIGATION COULD NOT BE PERFORMED. THE ROOT CAUSE AND/OR PATIENT OUTCOME BEYOND THAT WHICH WAS DOCUMENTED IN THE ARTICLE COULD NOT BE CONFIRMED NOR CONCLUDED; THEREFORE, NO FURTHER MEDICAL ASSESSMENT IS WARRANTED AT THIS TIME. SHOULD ADDITIONAL MEDICAL INFORMATION BE PROVIDED THIS COMPLAINT WILL BE RE-ASSESSED. WITHOUT RETURN OF THE ACTUAL DEVICES OR FURTHER INFORMATION WE CANNOT FURTHER INVESTIGATE THE DETAILS SUPPLIED IN THIS COMPLAINT, OUR INVESTIGATION REMAINS INCONCLUSIVE, AND A DEFINITIVE ROOT CAUSE CANNOT BE DETERMINED. BASED ON THE LIMITED INFORMATION PROVIDED WE ARE UNABLE TO SPECULATE ON SPECIFIC FACTORS KNOWN TO CONTRIBUTE TO THE ALLEGED FAULT. IF THE PRODUCTS OR ADDITIONAL INFORMATION BECOME AVAILABLE IN THE FUTURE, THIS CASE WILL BE REOPENED. NO PREVENTATIVE OR CORRECTIVE ACTION HAS BEEN INITIATED AS A RESULT OF THIS INVESTIGATION.

Description of Event or Problem · 0

IT WAS REPORTED THAT, ON LITERATURE REVIEW "RESULTS OF THE FIRST U.S FDA - APPROVED HIP RESURFACING DEVICE AT 10 - YEAR FOLLOW - UP." OSTEOLYSIS WAS IDENTIFIED IN FOUR (4) OUT OF TWO HUNDRED EIGHTEEN (218) FEMORAL COMPONENTS IMPLANTED ON PATIENTS WHO UNDERWENT PRIMARY SURGERY WITH A BHR RESURFACING CONSTRUCT. ALTHOUGH IT IS UNKNOWN HOW THIS EVENT WAS ADDRESSED ON EACH PATIENT, A REVISION SURGERY WAS NOT REQUIRED. FURTHER INFORMATION WAS NOT PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2808213 UNKN BIRMINGHAM HIP RESURFACING (BHR) HEAD PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/METAL, RESURFACING NXT SMITH & NEPHEW ORTHOPAEDICS LTD UNK

Patients

Seq Age Sex Outcome Treatment
1 Unknown Required Intervention UNKN BIRMINGHAM HIP RESURFACING (BHR) CUP UNKN TY